Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | SHR-4602 |
| Synonyms | |
| Therapy Description |
SHR-4602 is an antibody-drug conjugate (ADC) comprising an antibody against ERBB2 (HER2) linked to a TOPO1 inhibitor, which potentially decreases tumor growth (Cancer Res (2024) 84 (6_Supplement): 3195). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| SHR-4602 | SHR4602|SHR 4602 | HER2 (ERBB2) Antibody-Drug Conjugate 35 | SHR-4602 is an antibody-drug conjugate (ADC) comprising an antibody against ERBB2 (HER2) linked to a TOPO1 inhibitor, which potentially decreases tumor growth (Cancer Res (2024) 84 (6_Supplement): 3195). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06560138 | Phase I | SHR-4602 | A Trial of SHR-4602 Infusion in Patients With SHR-4602 in Subjects With HER2-expressing or HER2-mutated Locally Advanced or Metastatic Solid Tumors | Withdrawn | AUS | 0 |